Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

NARecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Recurrent Atypical/malignant Meningioma
Interventions
DRUG

Apatinib Mesylate

"Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator."

Trial Locations (1)

Unknown

RECRUITING

Sanbo Brain Hospital, Beijing

All Listed Sponsors
lead

Beijing Sanbo Brain Hospital

OTHER